Most of the best-known brain-computer interface developers, Neuralink, Synchron, Precision Neuroscience and Paradromics among them, are private, which leaves public-market investors few direct ways to own the field. ARK Invest has now filed to launch an exchange-traded fund built around it.
The filing
ARK ETF Trust, the trust that issues the ETFs of Cathie Wood’s ARK Investment Management, filed a preliminary prospectus with the US Securities and Exchange Commission on 6 November 2026 for 14 new thematic ETFs. One is the ARK Brain Computer Interfaces & Surgical Robotics ETF. The others cover neobanks, agentic cyber defence, neoclouds, frontier AI labs, AI agents, orbital data centres, robotaxis, humanoid robots and physical AI, longevity, peptides, tokenised market infrastructure, AI factories and functional cures.
ARK proposed that the filing take effect 75 days after it was made, around 20 January 2027. Tickers, fees and the listing exchange are left blank or in brackets, and the amendment covering the new funds is not yet effective.
What the fund would hold
The fund would be actively managed and invest at least 80 per cent of its assets in line with its brain-computer interface and surgical robotics strategy, a basket the filing says can also count government securities and money market instruments. Its objective is long-term growth of capital. The prospectus defines brain-computer interface companies as those ARK believes are developing or commercialising devices that create a direct communication link between the nervous system, especially the brain, and an external device such as a computer, robotic limb or medical implant. Surgical robotics companies, also chosen on ARK’s judgement, include dedicated surgical robot makers and diversified medical device companies with material robotics revenue, across orthopaedics, soft-tissue surgery, urology, neurosurgery and related specialties.
It expects to gain exposure primarily through total return swaps, contracts in which one party pays a fixed or variable rate and the other pays the return of an underlying asset, including income and capital gains, and will also buy shares directly. It may invest in private equity and restricted securities. Its holdings will range from micro-cap to mega-cap companies, in the US and in developed and emerging foreign markets. It would be non-diversified, and the filing names health care, in brackets, as the sector where it would concentrate more than 25 per cent of its assets. Daniel White, William Scherer and Tasha Keeney are named as portfolio managers, also in brackets, so the names may change.
Among the risks the prospectus lists: development is difficult, time-consuming and expensive, US Food and Drug Administration approval or clearance of surgical robotic systems is typically lengthy and uncertain, and companies may fail to build low-cost manufacturing at the volumes needed for commercial products.
ARK and Neuralink
ARK already owns part of Neuralink through a different product. It added Neuralink to its ARK Venture Fund in 2025, investing in the company’s Series E round. The ETF prospectus does not name any intended holdings.
Why it matters
A dedicated fund from a large thematic manager would give public-market investors a packaged way to own the field, and signals that brain-computer interfaces are being treated as an investable category. Pairing the theme with surgical robotics gives the fund a larger pool of listed companies, since surgical robot makers and diversified device groups already trade publicly. The permission to hold private and restricted securities, and minority interests in special purpose vehicles run by others, means the fund could own stakes in private developers.
Not disclosed
The filing does not give tickers, fees, a launch date or any intended holdings, and does not say how much of the fund would go to brain-computer interface companies against surgical robotics, or who its swap counterparties would be.
What to watch
Whether the filing takes effect and the fund lists in early 2027.
Whether its first holdings include private developers such as Neuralink.
Whether other ETF issuers file funds dedicated to brain-computer interfaces.
Sources
Primary:
- ARK ETF Trust: Form N-1A post-effective amendment (485APOS), preliminary prospectus for 14 thematic ETFs, 6 November 2026
- SEC EDGAR: filing index for ARK ETF Trust, accession 0001213900-26-116724
- ARK Invest: ARK Venture Q2 2025 update
- ARK Invest: Neuralink investment thesis, May 2026
Coverage:
Cross-reference to prior InsideBCI coverage: